Litcius/Paper detail

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

Emily Nickles, Bhushan Dharmadhikari, Yating Li, Robert J. Walsh, Liang Piu Koh, Michelle Poon, Lip Kun Tan, Lingzhi Wang, Yvonne Ang, Yugarajah Asokumaran, Wan Qin Chong, Yiqing Huang, Kwok Seng Loh, Joshua K. Tay, Ross A. Soo, Mickey Koh, Liam Pock Ho, Marieta Chan, Madelaine Niam, Melissa Soh, Yen Hoon Luah, Chwee Ming Lim, Nivashini Kaliaperumal, Veonice Bijin Au, Najwa Binte Said Nasir Talib, Reina Sng, John E. Connolly, Boon Cher Goh, Herbert Schwarz

2021Cancer Immunology Immunotherapy28 citationsDOIOpen Access PDF

Topics & Concepts

Nasopharyngeal carcinomaCD137MedicineCD8AntigenImmunologyInternal medicineImmunotherapyImmune systemRadiation therapyImmunotherapy and Immune ResponsesViral-associated cancers and disordersHead and Neck Cancer Studies
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit | Litcius